Development
Early in development, the mechanism of action, indication(s) for therapy and dosing regimens tested may suggest that serious adverse events, patient selection/monitoring or compliance could become issues. Then, as more Phase I and Phase II data become available, it may be increasingly evident that your compound or device poses a significant safety risk or may demand more complex management than physicians may be expecting.
Situation analyses, patient and treatment maps, minimum and target product profiles and a commercialization plan can all benefit from early consideration of risk. Even factoring risk mitigation into market research that generates preference shares to support forecasts and pricing can yield more actionable data for management. In fact, robust risk mitigation can support competitive differentiation.
Potential regulatory delays or missteps can be avoided by developing an early contingency plan with an independent risk mitigation specialist -- while also looking to drive appropriate scripts at launch.
ParagonRx can help you leverage your early stage data, assess where you are and make appropriate recommendations -- so you stay "ahead of the pack" in a competitive environment.